Lessons from the TOPCAT Trial
Authors:
- John J.V. McMurrayJMJohn J.V. McMurray
- Christopher O'COnnorCOChristopher O'COnnor
- 10 April 2014
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 370 (15) , 1453-1454
Abstract
Some patients with the clinical syndrome of heart failure have a normal or near-normal left ventricular ejection fraction.13 To date, no treatment has been shown to improve outcomes in this condition, usually designated heart failure with a preserved ejection fraction.2,3 The care of such patients can be difficult and is typically limited to efforts to relieve symptoms.Mineralocorticoid-receptor antagonists such as spironolactone are highly efficacious in patients with heart failure and a reduced ejection fraction.4,5 Pitt et al. now report in the Journal the findings of a trial comparing spironolactone with placebo in patients with heart failure . . .Keywords
This publication has 9 references indexed in Scilit:
- Spironolactone for Heart Failure with Preserved Ejection FractionNew England Journal of Medicine, 2014
- 2013 ACCF/AHA Guideline for the Management of Heart FailureJACC, 2013
- What Have We Learned About Patients With Heart Failure and Preserved Ejection Fraction From DIG-PEF, CHARM-Preserved, and I-PRESERVE?JACC, 2012
- Implications of geographical variation on clinical outcomes of cardiovascular trialsAmerican Heart Journal, 2012
- ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012European Journal of Heart Failure, 2012
- Influence of Global Region on Outcomes in Heart Failure Beta-Blocker TrialsJACC, 2011
- Eplerenone in Patients with Systolic Heart Failure and Mild SymptomsNew England Journal of Medicine, 2011
- Irbesartan in Patients with Heart Failure and Preserved Ejection FractionNew England Journal of Medicine, 2008
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999